What Is GLP-1? The Science, History & Uses of the Most Important Hormone in Modern Medicine
A plain-language explainer from the pharmacists at 79th Street Pharmacy on the Upper West Side - what GLP-1 actually is, how it was discovered, what the research shows, and why it changed medicine.
Almost every week someone at our counter asks a version of the same question: "What is GLP-1, really?" People know the brand names - Ozempic, Wegovy, Mounjaro, Zepbound - long before they know what the underlying hormone does. This guide answers the question properly: the biology, the discovery story, the approved uses, what the trials actually found, and why researchers describe GLP-1 as one of the most consequential inventions in modern pharmacology.
GLP-1 in One Sentence
GLP-1 stands for glucagon-like peptide-1: a 30-amino-acid hormone released by L-cells in your small intestine within minutes of eating, which tells the pancreas to release insulin, tells the liver to stop dumping sugar, slows the stomach, and tells the brain you have had enough.
It is a gut hormone that behaves like a messenger between your digestive tract and your metabolism. Everyone reading this makes GLP-1 several times a day. The medicines simply make that signal last far longer than nature allows.
The Incretin Effect: The Observation That Started Everything
In the 1960s, researchers noticed something odd. When glucose was given by mouth, the insulin response was far larger than when the same amount of glucose was delivered intravenously. The difference - roughly 50-70% of the insulin response after a normal meal - had to be coming from the gut itself. This became known as the incretin effect.
Two hormones were eventually shown to be responsible: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. In type 2 diabetes, the incretin effect is blunted. Restoring it became a therapeutic target - but there was a problem.
The Problem: GLP-1 Lasts About Two Minutes
Native GLP-1 is destroyed almost instantly by an enzyme called DPP-4 (dipeptidyl peptidase-4). Its half-life is roughly one to two minutes. You cannot make a drug out of a molecule that disappears before it reaches the tissue you are aiming at. For years this was the wall the field kept hitting.
The Gila Monster: Where the Invention Actually Came From
The breakthrough came from an unlikely place. In the early 1990s, researchers studying the venom of the Gila monster - a slow, heavy-bodied lizard native to the American Southwest - isolated a peptide they named exendin-4. It shared about 53% of its sequence with human GLP-1, activated the same receptor, and - critically - was resistant to DPP-4. Instead of two minutes, it lasted hours.
Exendin-4 became exenatide (Byetta), approved in 2005 as the first GLP-1 receptor agonist. That single insight - copy the signal, change the parts the enzyme grabs - is the design principle behind every GLP-1 medication that followed.
How the Modern Molecules Were Engineered
After exenatide, chemists took the human GLP-1 backbone and modified it in three main ways:
- Amino acid substitution at the DPP-4 cleavage site so the enzyme can no longer cut the molecule.
- Fatty acid attachment (acylation) so the drug binds reversibly to albumin in the blood and is released slowly - this is what turns a two-minute hormone into a once-weekly injection.
- Fusion or absorption enhancers - dulaglutide fuses the peptide to an antibody fragment; oral semaglutide is co-formulated with an absorption enhancer so a peptide can survive the stomach at all, which was long considered impossible.
The most recent step is dual agonism. Tirzepatide activates both the GIP and GLP-1 receptors with a single molecule - reviving GIP, the other incretin hormone that had been written off for decades.
What GLP-1 Does in the Body
| Where | What GLP-1 does | Why it matters |
|---|---|---|
| Pancreas (beta cells) | Increases insulin release, but only when glucose is elevated | Glucose-dependent action means low intrinsic risk of hypoglycemia |
| Pancreas (alpha cells) | Suppresses glucagon | Less sugar released by the liver between meals |
| Stomach | Slows gastric emptying | Flatter post-meal glucose curve; also the source of nausea and fullness |
| Brain (hypothalamus, brainstem) | Increases satiety, reduces food reward signaling | The "food noise" quieting patients describe; drives weight loss |
| Heart & vasculature | Receptor activity plus indirect metabolic effects | Cardiovascular outcome benefit seen in large trials |
| Kidney | Reduced albuminuria, slower eGFR decline in trials | Basis for chronic kidney disease indications in type 2 diabetes |
What GLP-1 Medications Are Approved to Treat
Indications differ by product, and the same molecule can be approved under two brand names for two different uses (semaglutide as Ozempic for diabetes and Wegovy for weight management; tirzepatide as Mounjaro and Zepbound). Broadly, FDA-approved uses across the class include:
- Type 2 diabetes - glycemic control alongside diet and exercise
- Chronic weight management in adults with obesity, or overweight with a weight-related condition
- Reducing the risk of major cardiovascular events in certain adults with type 2 diabetes or with established cardiovascular disease
- Chronic kidney disease in adults with type 2 diabetes
- Moderate-to-severe obstructive sleep apnea in adults with obesity
GLP-1 medicines are not approved for cosmetic weight loss, are not appropriate for everyone, and always require a prescription and clinical evaluation.
The Research That Changed Practice
Three lines of evidence moved GLP-1 from a diabetes drug to a category of its own:
- Cardiovascular outcome trials. Large randomized trials in the late 2010s showed reductions in major adverse cardiovascular events with several GLP-1 agonists - a benefit beyond blood sugar lowering, which regulators later reflected in labeling.
- Dedicated obesity trials. Weight-management programs demonstrated mean weight reductions in the mid-teens percent with semaglutide 2.4 mg and roughly 20%-range reductions at the highest tirzepatide doses - results previously seen only with bariatric surgery.
- Organ-specific outcome trials. Kidney outcomes in type 2 diabetes, sleep apnea severity, heart failure with preserved ejection fraction and obesity, and secondary cardiovascular prevention in people without diabetes have all been studied with positive results in specific populations.
Active research areas now include metabolic liver disease (MASH), addiction and craving behavior, neurodegenerative disease, muscle-sparing combination therapy, and oral small-molecule GLP-1 agonists that would not require peptide manufacturing at all.
What Makes GLP-1 a Genuinely Unique Invention
- It is a copied signal, not a blunt instrument. Rather than forcing insulin or blocking an enzyme, it amplifies a pathway the body already uses - which is why the insulin effect is glucose-dependent.
- It crossed a species boundary. The usable version of the molecule came from lizard venom, not human biology. Basic research on an animal nobody was studying for diabetes produced a multi-billion-dollar drug class.
- It solved the peptide half-life problem. Albumin-binding fatty acid chemistry turned a two-minute hormone into a weekly injection, a template now applied well beyond metabolism.
- It made an oral peptide real. Delivering a peptide through the stomach was considered a dead end until absorption-enhancer co-formulation worked.
- It reframed obesity as treatable biology. Consistent, durable, medication-driven weight loss shifted the clinical conversation away from willpower.
- One pathway, many organs. Heart, kidney, liver, airway, and brain effects from a single receptor target is unusual in pharmacology.
Side Effects and Honest Caveats
The most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reflux, usually worst during dose escalation. Less common but important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, and - in people taking insulin or a sulfonylurea - hypoglycemia. Products in this class carry a boxed warning regarding thyroid C-cell tumors observed in rodents; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
Weight regain after stopping is common, because the underlying appetite signaling returns to baseline. Preserving lean mass with adequate protein and resistance training matters. None of this is a reason to avoid the class - it is a reason to be on it with a clinician and a pharmacist who are paying attention.
Filling a GLP-1 Prescription in NYC
Understanding the science is the easy part. Getting the medication - in stock, at a price that makes sense, with the authorization actually approved - is where most New Yorkers get stuck. At 79th Street Pharmacy we keep the major GLP-1 brands on hand, enroll eligible patients in manufacturer savings programs automatically, coordinate prior authorization paperwork with your prescriber's office so their staff can submit it quickly, and deliver refrigerated across Manhattan and Brooklyn.
- GLP-1 pharmacy in NYC - all brands
- Current GLP-1 and weight-loss pricing
- GLP-1 coupons and savings cards
- Transfer an existing GLP-1 prescription
Frequently Asked Questions
What does GLP-1 stand for?
Glucagon-like peptide-1 - a natural incretin hormone released by the small intestine after eating.
How do GLP-1 medications work?
They activate the same receptor as the natural hormone but resist the DPP-4 enzyme, so one dose keeps the signal going for days instead of minutes.
What is GLP-1 used for?
Depending on the product: type 2 diabetes, chronic weight management, cardiovascular risk reduction, chronic kidney disease in type 2 diabetes, and obstructive sleep apnea in adults with obesity.
Which medications are GLP-1 drugs?
Semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist.
Why is GLP-1 called a landmark discovery?
It is the first medication class to produce surgery-level weight loss while also improving glucose control and cardiovascular outcomes - built on a hormone copied from a lizard and re-engineered to last.
Where can I fill a GLP-1 prescription near me in NYC?
79th Street Pharmacy, 179 W 79th Street on the Upper West Side - same-day pickup or free refrigerated delivery across Manhattan and Brooklyn.
The Bottom Line
GLP-1 is not a diet drug that got lucky. It is a hormone your body already uses, isolated through decades of basic research, made durable by clever chemistry, and validated in some of the largest outcome trials in modern medicine. Whether it is right for you is a conversation with your provider - and once it is prescribed, getting it filled quickly and affordably is our job.
This article is educational and is not medical advice. Prescription required. Talk with your healthcare provider about whether a GLP-1 medication is appropriate for you.